Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report)’s share price was down 0.6% during mid-day trading on Monday . The stock traded as low as $9.05 and last traded at $9.28. Approximately 660,760 shares traded hands during mid-day trading, an increase of 96% from the average daily volume of 337,931 shares. The stock had previously closed at $9.34.
Silverback Therapeutics Trading Down 0.6%
The company has a market cap of $334.62 million, a P/E ratio of -3.83 and a beta of 0.60. The business’s 50 day simple moving average is $10.43 and its 200 day simple moving average is $10.29.
Silverback Therapeutics Company Profile
Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.
Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.
See Also
- Five stocks we like better than Silverback Therapeutics
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- I’m 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)
- ALERT: Drop these 5 stocks before the market opens tomorrow!
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
